"Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results." by Omid Hamid

Selected Works of Walter J. Urba, MD, PhD

Article

Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results.

Journal of Clinical Oncology (2012)

Omid Hamid, University of Sydney
Wen-Jen Hwu, University of Texas MD Anderson Cancer Center
Jon M. Richards, Advocate Lutheran General Hospital
Jeffrey S. Weber, University of South Florida
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center
Mario Sznol, Yale University
David R. Minor, California Pacific Medical Center
Anna C. Pavlick, New York University
Walter John Urba
F. Stephen Hodi, Harvard University
Arvin Yang, Colorado State University
Tracy Michener, Bristol-Myers Squibb
Agnes Balogh, Bristol-Myers Squibb
David F. McDermott, Harvard University

Link

Disciplines

Publication Date

May 20, 2012

Citation Information

Omid Hamid, Wen-Jen Hwu, Jon M. Richards, Jeffrey S. Weber, et al.. "Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results." Journal of Clinical Oncology Vol. 30 (2012) p. 8508
Available at: http://works.bepress.com/walter-urba/155/